Clinical Trails


Psychedelic trials 2021
MAPS
Post-traumatic stress disorder (PTSD)
MDMA
Phase III
Compass Pathways
Treatment-resistant depression (TRD)
COMP360
Phase II
Usona Institute
Major depressive disorder (MDD)
Psilocybin
Phase II
MAPS
Eating disorders (anorexia nervosa and binge-eating disorder)
MDMA
II
MAPS
Anxiety associated with a life-threatening illness
MDMA
II
MAPS
Social anxiety in autistic adults
MDMA
II
MindMed
Anxiety
LSD
II
MindMed
Cluster headaches
LSD
II
Seelos Therapeutics
Acute suicidal ideation and behaviour (ASIB) in major depressive disorder
SLS-002
II
Awakn Life Sciences
Alcohol use disorder
MDMA
II
B.More
Alcohol use disorder
Psilocybin
II
Braxia Scientific
Treatment-resistant depression
Psilocybin
II
Tryp Therapeutics
Overeating disorders
TRP-8802
II
Compass Pathways
Post-traumatic stress disorder (PTSD)
COMP360
II
Cybin
Major depressive disorder
CYB001
II
DemeRx Logo          
Opioid use disorder
DMX-NB1
II
Eleusis Logo 
Major depressive disorder (adjunctive treatment)
ELE-Ket+
II
Incannex       
Generalized anxiety disorder
Psilocybin
II
MAPS Logo  
CBCT for PTSD
MDMA
II
MindMed
Attention deficit hyperactivity disorder (ADHD)
LSD
II
MindMed
Undisclosed severe pain indication
LSD
II
Mydecine Innovations
Post-traumatic stress disorder (PTSD)
Psilocybin
II
Perception Neuroscience    
Treatment-resistant depression (TRD)
PCN-101
II
Pharmather  
Levodopa-induced dyskinesia in patients with Parkinson’s disease
Ketamine
II
GH Research
Treatment-resistant depression (TRD)
GH001
I / II
Small Pharma
Major depressive disorder (MDD)
SPL026
I / II
DemeRx        
Opioid use disorder
DMX-1002
I / II
Beckley Psytech       
Undisclosed
5-MeO-DMT
I
Eleusis
Alzheimer’s Disease
ELE-LSD
I
MindMed      
Opioid use disorder
18-MC
I
MindMed      
Undisclosed
DMT
I
MindMed
Undisclosed
MDMA+LSD
I
MindMed
Undisclosed
Mescaline
I
MindMed
Ketanserin
I
Algernon Pharmaceuticals 
Ischemic stroke and post-stroke rehabilitation
AP-188
I
Beckley Psytech Logo         
Short-lasting unilaterial neuralgiform headache attacks (SUNHA)
Psilocybin
I
Ceruvia Lifesciences
Cluster headache
NYPRG-101
I
Ceruvia Lifesciences
Migraine
NYPRG-101
I
Ceruvia Lifesciences
Migraine
SYNP-101
I
Ceruvia Lifesciences
Cluster headache
SYNP-101
I
Ceruvia Lifesciences
Obsessive compulsive disorder
SYNP-101
I
Diamond Therapeutics       
Anxiety
Psilocybin
I
Entheon Biomedical Logo  
(Unspecified) Substance use disorder
DMT
I
Filament Health invite        
Undisclosed
PEX010
II
Health invite
Undisclosed
PEX020…
I
Filament Health invite        
Undisclosed
PEX030…
I
Journey Colab         
Alcohol use disorder
JOUR-001
I
MindMed
Social anxiety associated with Autism Spectrum Disorder
R-MDMA
I
Numinus logo           
Undisclosed
PSYBINA
I
Sacred Medicines     
Undisclosed

 

Ψ From Molecule to Mind — and beyond ∞

Top